RU2007116036A - Карбонильные соединения, которые могут применяться в качестве ингибиторов фактора коагуляции ха - Google Patents
Карбонильные соединения, которые могут применяться в качестве ингибиторов фактора коагуляции ха Download PDFInfo
- Publication number
- RU2007116036A RU2007116036A RU2007116036/04A RU2007116036A RU2007116036A RU 2007116036 A RU2007116036 A RU 2007116036A RU 2007116036/04 A RU2007116036/04 A RU 2007116036/04A RU 2007116036 A RU2007116036 A RU 2007116036A RU 2007116036 A RU2007116036 A RU 2007116036A
- Authority
- RU
- Russia
- Prior art keywords
- diyl
- monosubstituted
- hal
- salts
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 43
- 239000003112 inhibitor Substances 0.000 title claims 3
- 102000015081 Blood Coagulation Factors Human genes 0.000 title 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 title 1
- 239000003114 blood coagulation factor Substances 0.000 title 1
- -1 N 3 Chemical group 0.000 claims 93
- 150000003839 salts Chemical class 0.000 claims 36
- 239000012453 solvate Substances 0.000 claims 33
- 239000000203 mixture Substances 0.000 claims 30
- 125000004432 carbon atom Chemical group C* 0.000 claims 22
- 125000000217 alkyl group Chemical group 0.000 claims 19
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 17
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 11
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims 10
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 10
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 9
- 125000000623 heterocyclic group Chemical group 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 8
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 8
- 125000002950 monocyclic group Chemical group 0.000 claims 8
- 125000004076 pyridyl group Chemical group 0.000 claims 8
- 125000004434 sulfur atom Chemical group 0.000 claims 8
- 125000001544 thienyl group Chemical group 0.000 claims 8
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 claims 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 7
- 125000004430 oxygen atom Chemical group O* 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 208000007536 Thrombosis Diseases 0.000 claims 6
- 125000002619 bicyclic group Chemical group 0.000 claims 6
- 125000004429 atom Chemical group 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 5
- 229920006395 saturated elastomer Chemical group 0.000 claims 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 5
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 4
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 4
- 125000002837 carbocyclic group Chemical group 0.000 claims 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 4
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 4
- 125000005336 allyloxy group Chemical group 0.000 claims 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000002993 cycloalkylene group Chemical group 0.000 claims 3
- 125000004956 cyclohexylene group Chemical group 0.000 claims 3
- 125000002541 furyl group Chemical group 0.000 claims 3
- 125000002883 imidazolyl group Chemical group 0.000 claims 3
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 3
- 238000011477 surgical intervention Methods 0.000 claims 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 3
- 229920002554 vinyl polymer Polymers 0.000 claims 3
- 125000005962 1,4-oxazepanyl group Chemical group 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 2
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 2
- 206010008190 Cerebrovascular accident Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 206010020608 Hypercoagulation Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 208000001435 Thromboembolism Diseases 0.000 claims 2
- 208000009205 Tinnitus Diseases 0.000 claims 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 2
- 235000010290 biphenyl Nutrition 0.000 claims 2
- 239000004305 biphenyl Substances 0.000 claims 2
- 238000002316 cosmetic surgery Methods 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 125000002632 imidazolidinyl group Chemical group 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 208000030175 lameness Diseases 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000004526 pyridazin-2-yl group Chemical group N1N(C=CC=C1)* 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 201000005665 thrombophilia Diseases 0.000 claims 2
- 231100000886 tinnitus Toxicity 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- MZAGXDHQGXUDDX-JSRXJHBZSA-N (e,2z)-4-ethyl-2-hydroxyimino-5-nitrohex-3-enamide Chemical compound [O-][N+](=O)C(C)C(/CC)=C/C(=N/O)/C(N)=O MZAGXDHQGXUDDX-JSRXJHBZSA-N 0.000 claims 1
- 108010054265 Factor VIIa Proteins 0.000 claims 1
- 108010074860 Factor Xa Proteins 0.000 claims 1
- 210000001015 abdomen Anatomy 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 230000002612 cardiopulmonary effect Effects 0.000 claims 1
- 210000004351 coronary vessel Anatomy 0.000 claims 1
- 210000003709 heart valve Anatomy 0.000 claims 1
- 210000003127 knee Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000000399 orthopedic effect Effects 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 238000007631 vascular surgery Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Surgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004047254.8 | 2004-09-29 | ||
| DE102004047254A DE102004047254A1 (de) | 2004-09-29 | 2004-09-29 | Carbonylverbindungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2007116036A true RU2007116036A (ru) | 2008-11-10 |
Family
ID=35395743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007116036/04A RU2007116036A (ru) | 2004-09-29 | 2005-09-01 | Карбонильные соединения, которые могут применяться в качестве ингибиторов фактора коагуляции ха |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20080081814A1 (enExample) |
| EP (1) | EP1797071A1 (enExample) |
| JP (1) | JP2008514655A (enExample) |
| KR (1) | KR20070057878A (enExample) |
| CN (1) | CN101031561A (enExample) |
| AU (1) | AU2005289164A1 (enExample) |
| BR (1) | BRPI0515577A (enExample) |
| CA (1) | CA2581732A1 (enExample) |
| DE (1) | DE102004047254A1 (enExample) |
| MX (1) | MX2007003470A (enExample) |
| RU (1) | RU2007116036A (enExample) |
| WO (1) | WO2006034769A1 (enExample) |
| ZA (1) | ZA200703443B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
| USRE50453E1 (en) | 2006-04-07 | 2025-06-10 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
| US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| JP5420395B2 (ja) | 2006-04-07 | 2014-02-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｐ結合カセット輸送体の調節剤 |
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| US8673920B2 (en) | 2009-05-06 | 2014-03-18 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| RU2569678C2 (ru) | 2010-04-22 | 2015-11-27 | Вертекс Фармасьютикалз Инкорпорейтед | Способ получения циклоалкилкарбоксамидо-индольных соединений |
| EP2632465B1 (en) | 2010-10-27 | 2015-12-30 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| WO2012058134A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| ES2605164T3 (es) | 2011-08-19 | 2017-03-13 | Merck Sharp & Dohme Corp. | Inhibidores del canal de potasio de la médula renal externa |
| WO2013039802A1 (en) | 2011-09-16 | 2013-03-21 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| EP2771005B1 (en) | 2011-10-25 | 2016-05-18 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| EP2771004B1 (en) | 2011-10-25 | 2016-05-18 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| US9493474B2 (en) | 2011-10-31 | 2016-11-15 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| US9108947B2 (en) | 2011-10-31 | 2015-08-18 | Merck Sharp & Dohme Corp. | Inhibitors of the Renal Outer Medullary Potassium channel |
| EP2773199B1 (en) | 2011-10-31 | 2019-04-10 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| US9206199B2 (en) | 2011-12-16 | 2015-12-08 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| IN2014CN04174A (enExample) | 2011-12-22 | 2015-09-04 | Novartis Ag | |
| AU2013290444B2 (en) | 2012-07-16 | 2018-04-26 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof |
| AR092031A1 (es) | 2012-07-26 | 2015-03-18 | Merck Sharp & Dohme | Inhibidores del canal de potasio medular externo renal |
| WO2014085210A1 (en) | 2012-11-29 | 2014-06-05 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| WO2014099633A2 (en) | 2012-12-19 | 2014-06-26 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| EP2956142B1 (en) | 2013-02-18 | 2017-09-20 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| US9765074B2 (en) | 2013-03-15 | 2017-09-19 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| US9751881B2 (en) | 2013-07-31 | 2017-09-05 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| PL3925607T5 (pl) | 2014-04-15 | 2026-06-01 | Vertex Pharmaceuticals Incorporated | Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa |
| WO2016127358A1 (en) | 2015-02-12 | 2016-08-18 | Merck Sharp & Dohme Corp. | Inhibitors of renal outer medullary potassium channel |
| JP6980534B2 (ja) | 2015-06-25 | 2021-12-15 | ザ チルドレンズ メディカル センター コーポレーション | 造血幹細胞の増大、富化、および維持に関する方法および組成物 |
| WO2017161001A1 (en) | 2016-03-15 | 2017-09-21 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion |
| CN106674200B (zh) * | 2016-12-21 | 2019-04-12 | 西安交通大学 | 一种含有l-脯氨酰胺片段的化合物及其制备方法和应用 |
| CN108997200A (zh) * | 2018-07-17 | 2018-12-14 | 成都睿智化学研究有限公司 | 一种5-氨甲基-哌啶-2-酮的制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7030141B2 (en) * | 2001-11-29 | 2006-04-18 | Christopher Franklin Bigge | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade |
| PL377633A1 (pl) * | 2003-04-03 | 2006-02-06 | Merck Patent Gmbh | Związki karbonylowe |
| DE10329457A1 (de) * | 2003-04-03 | 2005-01-20 | Merck Patent Gmbh | Ethinylprolinderivate |
| DE102004045796A1 (de) * | 2004-09-22 | 2006-03-23 | Merck Patent Gmbh | Arzneimittel enthaltend Carbonylverbindungen sowie deren Verwendung |
-
2004
- 2004-09-29 DE DE102004047254A patent/DE102004047254A1/de not_active Withdrawn
-
2005
- 2005-09-01 WO PCT/EP2005/009418 patent/WO2006034769A1/de not_active Ceased
- 2005-09-01 CA CA002581732A patent/CA2581732A1/en not_active Abandoned
- 2005-09-01 KR KR1020077007053A patent/KR20070057878A/ko not_active Withdrawn
- 2005-09-01 RU RU2007116036/04A patent/RU2007116036A/ru unknown
- 2005-09-01 CN CNA2005800327898A patent/CN101031561A/zh active Pending
- 2005-09-01 US US11/576,207 patent/US20080081814A1/en not_active Abandoned
- 2005-09-01 JP JP2007533891A patent/JP2008514655A/ja active Pending
- 2005-09-01 MX MX2007003470A patent/MX2007003470A/es not_active Application Discontinuation
- 2005-09-01 AU AU2005289164A patent/AU2005289164A1/en not_active Abandoned
- 2005-09-01 EP EP05790356A patent/EP1797071A1/de not_active Withdrawn
- 2005-09-01 BR BRPI0515577-0A patent/BRPI0515577A/pt not_active Application Discontinuation
-
2007
- 2007-04-26 ZA ZA200703443A patent/ZA200703443B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2581732A1 (en) | 2006-04-06 |
| EP1797071A1 (de) | 2007-06-20 |
| US20080081814A1 (en) | 2008-04-03 |
| DE102004047254A1 (de) | 2006-04-13 |
| BRPI0515577A (pt) | 2008-07-29 |
| JP2008514655A (ja) | 2008-05-08 |
| CN101031561A (zh) | 2007-09-05 |
| ZA200703443B (en) | 2008-08-27 |
| MX2007003470A (es) | 2007-05-10 |
| AU2005289164A1 (en) | 2006-04-06 |
| WO2006034769A1 (de) | 2006-04-06 |
| KR20070057878A (ko) | 2007-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2007115157A (ru) | Лекарственные средства, содержащие карбонильные соединения, и их применение | |
| RU2002123350A (ru) | Дипептиднитрильные ингибиторы катепсина К | |
| JP5470046B2 (ja) | Ｐａｉ−１産生抑制剤 | |
| RU2004100302A (ru) | Амиды антраниловой кислоты с гетероарилсульфонильной боковой цепью, способ их получения, их применение в качестве лекарственного или диагностического средства, а также содержащие их фармацевтические композиции | |
| RU2003134544A (ru) | Амиды антраниловой кислоты, способы их получения, их применение в качестве антиаритмических средств, а также содержащие их фармацевтические композиции | |
| RU94043811A (ru) | Применение 2-фенил-3-ароилбензтиофенов для лечения менструальных симптомов, фармацевтические композиции | |
| KR20090031572A (ko) | 신나모일-피페라진 유도체 및 ｐａｒ-1 길항제로서의 용도 | |
| JPH01224316A (ja) | 医薬製剤 | |
| JP2007522135A5 (enExample) | ||
| TW200908977A (en) | Use of a PAR-1 antagonist for the treatment of atrial fibrillation | |
| US6127554A (en) | 2,4-bis[(4-amidino)phenyl]furans as anti-Pneumocystis carinii agents | |
| EP0682947B1 (en) | Medicament for therapeutic and prophylactic treatment of diseases caused by smooth muscle cell hyperplasia | |
| CZ298542B6 (cs) | Použití derivátu hydroxylaminu k príprave léciva pro lécbu a prevenci nemocí spojených s dysfunkcí vaskulárních endoteliálních bunek a farmaceutický prípravek tyto látky obsahující | |
| JP2004533462A (ja) | 血管症の治療のための有機ナイトレートをベースとする化合物 | |
| RU2002105518A (ru) | Гетероциклические соединения, ингибирующие ангиогенез | |
| MXPA02001740A (es) | Uso de bis-sulfonamidas para producir medicinas para la profilaxis o tratamiento de hiperlipidemia. | |
| RU2006125380A (ru) | Производные карбоксамида | |
| RU2006137661A (ru) | Новые производные пирролидин-3, 4-дикарбоксамида | |
| RU2001121989A (ru) | Производные (1-фенацил-3-фенил-3-пиперидилэтил)пиперидина, способы их получения и содержащие их фармацевтические композиции | |
| WO2001032164A1 (en) | Inhibitor for 20-hete-yielding enzyme | |
| JPH06785B2 (ja) | チエノピリジン誘導体、その製造法及びそれを含有する医薬組成物 | |
| JP2962186B2 (ja) | ピペリジン誘導体及びそれを含有するセロトニン拮抗薬 | |
| WO1999043318A1 (en) | Lp(a)-LOWERING AGENTS AND APOPROTEIN (a) PRODUCTION INHIBTORS | |
| JPS6092279A (ja) | ２‐（ｎ‐ピロリジノ）‐３‐イソブトキシ‐ｎ‐置換‐フエニル‐ｎ‐ベンジル‐プロピルアミン、その製造およびその医薬としての使用 | |
| RU97109002A (ru) | Замещенные 1-нафтоилгуанидины, способ их получения и лекарственное средство на их основе |